Top

International Journal of Clinical Oncology

Published in:

01-04-2016 | Introduction to Invited Review Articles

Development and future directions of antiangiogenic therapy in hepatocellular carcinoma

Author: Akinobu Taketomi

Published in: International Journal of Clinical Oncology | Issue 2/2016

Excerpt

Angiogenesis is a promising therapeutic target in treatments aimed at inhibiting tumor growth. Since the study published by Folkman in 1971 that demonstrated that tumor growth is angiogenesis-dependent [1], research has focused on identifying new therapeutic agents that can inhibit angiogenesis. In 2004, bevacizumab was developed as a potent inhibitor of vascular endothelial growth factor (VEGF), and this agent demonstrated modest antitumor activity when combined with chemotherapy. Currently, inhibition of angiogenesis has become a standard treatment option for several tumor types, including colorectal cancer, glioblastoma and ovarian cancer. …

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186CrossRefPubMed

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed

Yamada K, Maishi N, Akiyama K et al (2015) CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property. Int J Cancer 137:2825–2836CrossRefPubMed

Title: Development and future directions of antiangiogenic therapy in hepatocellular carcinoma
Author: Akinobu Taketomi
Publication date: 01-04-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-0965-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2016

Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients

Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

Tumor angiogenesis—characteristics of tumor endothelial cells

Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy

The processus vaginalis transection method is superior to the simple prophylactic procedure for prevention of inguinal hernia after radical prostatectomy

R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer